title: [1998 prognosis of left ventricular dysfunction in a maximum care non-university hospital. Analysis of the Ludwigshafen LVD Registry].
abstract: BACKGROUND
  Prognostic data on heart failure rely on epidemiological studies or large clinical trials. These data are not to transfer easily on everyday practice.
  
  
  OBJECTIVE
  To assess the prognosis of left ventricular dysfunction under the therapeutic conditions of the 1990s.
  
  
  METHODS
  Nonuniversity tertiary care hospital.
  
  
  METHODS
  Since January 1995 consecutive and complete registry of all inpatients presenting with a left ventricular dysfunction (EF < 45%). No exclusion criteria.
  
  
  RESULTS
  n = 512, mean age 64 years, 77% male, mean NYHA class 2.5, left ventricular EF 31%.
  
  
  BACKGROUND
  58% coronary heart disease, 28% dilated cardiomyopathy. Medical treatment consisting of 91% ACE inhibitors, ACE inhibitor dosage 52% of the recommended dose, 42% beta-blockers, 70% diuretics, and 63% digitalis. Follow-up completeness 95.5%. One-year mortality 64/489 patients (13.9%). Determinants of mortality: NYHA III/IV, EF < 30%, malignant disease, age > 75 years.
  
  
  CONCLUSIONS
  In spite of the aforementioned medical treatment and a proportion of 14.8% implanted defibrillators in 1998, the one-year mortality of ventricular dysfunction is as high as 13.9%. In everyday practice the prognostic effect of ACE inhibition and beta-blockade is not completely utilized.
authors.affiliation: Diakoniekrankenhaus Rotenburg.
authors.forename: G
authors.initials: G
authors.lastname: Taubert
authors.forename: T
authors.initials: T
authors.lastname: Kottmann
authors.forename: A K
authors.initials: AK
authors.lastname: Gitt
authors.forename: R
authors.initials: R
authors.lastname: Winkler
authors.forename: C
authors.initials: C
authors.lastname: Bergmeier
authors.forename: T
authors.initials: T
authors.lastname: Kleemann
authors.forename: K
authors.initials: K
authors.lastname: Seidl
authors.forename: J
authors.initials: J
authors.lastname: Senges
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002423:Cause of Death; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005858:Germany; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data; D015996:Survival Rate; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000401:mortality*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004071:Digitalis Glycosides; D004232:Diuretics